Pfizer, a US giant pharmaceutical company, said it expects that the Food and Drug Administration (FDA) is going to license for the anti-Corona vaccine for children, at the age of 12-15 years, early next week.
Albert Burla, CEO of Pfizer told investors via a telephone conference, that the license for the children's vaccine is expected very soon.
He pointed out the company also expects to get the data of safety of the second stage of using its vaccine for pregnant women by the last day of July or early days of August.
Late in March, the company announced that it will ask the FDA to widen the spectrum of licenses of its vaccines in emergency cases to allow youths to be vaccinated.
The company indicated that clinical trials revealed its vaccines stir strong responses of the antibodies in teenagers at the age of 12 to 15 years.
Experts of the company conduct studies to define the benefits and safety of vaccination of young people.
Pfizer plans to submit two requests next September to the FDA to license using of its vaccines in emergency cases, especially with children at the age of 2 to 5 years as well as children at the age of 5 to 11 years.
On the other hand, Burla said on April 28, that a new medicine that treats the Coronavirus (also known as COVID-19) and is taken by the mouth may be produced and introduced to the markets across the world by the end of the next year.
He added that experts of the company are working now on two medicines: the first is administrated by the mouth and the second one taken by injection.
The CEO of Pfizer revealed that the company began an early phase of clinical trials for an oral drug late last month, and the drug blocks the “protease”, an important enzyme that the virus needs to reproduce when it invades the human body.
Follow the latest news on Google News
